Correlation between serum miR-127, miR-147a, miR-146b and the severity and prognosis of acute respiratory distress syndrome in premature infants
Main Article Content
Abstract
Objective: To explore the correlation between serum microRNA-127 (miR-127), miR-147a, miR-146b and the severity and prognosis of acute respiratory distress syndrome (ARDS) in premature infants. Methods: Eighty premature infants with ARDS admitted to our hospital from October 2020 to October 2023 were regarded as the observation subjects (ARDS group). 94 healthy newborns born during the same period in our hospital were as the control group. QRT-PCR method was applied to detect the relative expression levels of miR-127, miR-147a, and miR-146b in serum. According to the oxygenation index (OI), the severity of premature infants was evaluated and the infants were separated into mild group (27 cases), moderate group (37 cases), and severe group (16 cases). Receiver operating characteristic curve (ROC) was applied to analyze the diagnostic value of serum miR-127, miR-147a, and miR-146b for death in premature infants with ARDS. The comparison of area under the curve (AUC) was conducted through Z-test. Multivariate logistic regression was applied to analyze the influencing factors of death in premature infants with ARDS. Results: The expression level of serum miR-127 was higher in the ARDS group compared to the control group, while the expression levels of miR-147a and miR-146b were lower (P < 0.05). The expression level of serum miR-127 increased in the moderate and severe groups compared to the mild group, while the expression levels of miR-147a and miR-146b decreased (P < 0.05). The expression level of serum miR-127 increased in the severe group compared to the moderate group, while the expression levels of miR-147a and miR-146b decreased (P < 0.05). There was no statistically obvious difference between the survival group and the death group in terms of birth mode, gender, birth weight, assisted ventilation method, gestational age, frequency of pulmonary surfactant (PS) use, day age, hypoalbuminemia, and Apgar score (P > 0.05). The expression level of serum miR-127 was higher in the death group than in the survival group, while the expression levels of miR-147a and miR-146b were lower (P < 0.05). MiR-127 was a risk factor for death during hospitalization in premature infants with ARDS, while miR-147a and miR-146b were protective factors (P < 0.05). The AUC of serum miR-127, miR-147a, and miR-146b alone and in combination for diagnosing death in premature infant with ARDS was 0.825, 0.905, 0.873, and 0.977, respectively. The combined diagnostic efficacy of the three was the best (P < 0.05). Conclusion: The serum miR-127 level in premature infants with ARDS increases, while the levels of miR-147a and miR-146b decrease. They are correlated with the severity of the disease and have certain diagnostic value for the prognosis.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
References
Xu Qianjin, Zhu Peng, Shi Zhongshan, et al., “Assessment and control of respiratory drive in acute respiratory distress syndrome [J],” National Medical Journal of China, vol. 102, no. 36, pp. 2839–2843, 2022.
Verder H, Heiring C, Schousboe P, “Surfactant therapy of respiratory distress syndrome,” Ugeskr Laeger, vol. 183, no. 44, pp. 1–12, 2021.
Zhang Yongjun, Lü Huili, Liao Yufeng, et al., “Predictive value of plasma miR-127 and IL-32 for the prognosis of patients with acute lung injury [J],” Shandong Medical Journal, vol. 61, no. 7, pp. 20–23, 2021.
Jiao Yan, Li Dan, Liu Wendong, et al., “Expression of miR-147a and miR-217 in children with pneumonia and their correlation with pulmonary function and inflammatory factors [J],” Chinese Journal of Maternal and Child Health Research, vol. 33, no. 10, pp. 54–58, 2022.
Li Wenjie, Pan Yongliang, Huang Xiaomin, et al., “Relationship of serum miR-146b and ICAM-1 with disease severity and prognosis in patients with acute respiratory distress syndrome [J],” Guangxi Medical Journal, vol. 45, no. 10, pp. 1137–1142, 1152, 2023.
Neonatologist Branch of Chinese Medical Doctor Association, “Montreux criteria for neonatal acute respiratory distress syndrome (2017 edition)[J],” Chinese Journal of Applied Clinical Pediatrics, vol. 32, no. 19, pp. 1456– 1458, 2017.
Moharana S, Jain D, Bhardwaj N, et al., “Pressure support ventilation-pro decreases propofol consumption and improves postoperative oxygenation index compared with pressure-controlled ventilation in children undergoing ambulatory surgery: a randomized controlled trial[J],” Can J Anaesth, vol. 67, no. 4, pp. 445–451, 2020.
Meyer NJ, Gattinoni L, Calfee CS, “Acute respiratory distress syndrome[J],” Lancet, vol. 398, no. 10300, pp. 622–637, 2021.
Sweet DG, Carnielli VP, Greisen G, et al., “European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update[J],” Neonatology, vol. 120, no. 1, pp. 3–23, 2023.
Li Yinping, Li Tanshi, Shen Hong, “Research progress of liquid ventilation in the treatment of acute respiratory distress syndrome [J],” Chinese Journal of Critical Care Medicine, vol. 21, no. 1, pp. 61–62, 2001.
Hao Dahai, Gong Ming, “Research progress on the mechanism of miRNA action [J],” Genomics and Applied Biology, vol. 39, no. 8, pp. 3647–3657, 2020.
Ha Zonglan, Ma Lina, Ma Qiong, et al., “Predictive value of miR-146a and miR-127 for clinical risk and prognosis in elderly patients with severe pneumonia [J],” Chinese Journal of Emergency Resuscitation and Disaster Medicine, vol. 17, no. 9, pp. 1194–1197, 2022.
Gusar VA, Timofeeva AV, Chagovets VV, et al., “Interrelation between miRNAs Expression Associated with Redox State Fluctuations, Immune and Inflammatory Response Activation, and Neonatal Outcomes in Complicated Pregnancy, Accompanied by Placental Insufficiency,” Antioxidants (Basel)[J], vol. 12, no. 1, pp. 1–24, 2022.
Gong Juan, Zhang Dong, “Expression and clinical significance of serum lncRNA SNORD16 and miR-147a in patients with severe pneumonia [J],” Shaanxi Medical Journal, vol. 52, no. 1, pp. 75–78, 82, 2023.
Xu Y, Zhan X, “lncRNA KCNQ1OT1 regulated high glucose-induced proliferation, oxidative stress, extracellular matrix accumulation, and inflammation by miR-147a/SOX6 in diabetic nephropathy (DN)[J],” Endocr J, vol. 69, no. 5, pp. 511–522, 2022.
Liu M, Li W, Song F, et al., “Silencing of lncRNA MIAT alleviates LPS-induced pneumonia via regulating miR-147a/NKAP/NF-κB axis[J],” Aging (Albany NY), vol. 13, no. 2, pp. 2506–2518, 2020.
Gao W, Zhang Y, “Depression of lncRNA MINCR antagonizes LPS-evoked acute injury and inflammatory response via miR-146b-5p and the TRAF6-NFkB signaling[J],” Mol Med, vol. 27, no. 1, pp. 1–14, 2021.
Liu Y, Zhu JQ, Jin XH, et al., “Up-regulation of miR-146b-3p protects septic mice with acute respiratory distress syndrome by inhibiting PI3K/AKT signaling pathway[J],” J Bioenerg Biomembr, vol. 52, no. 4, pp. 229–236, 2020.
Chen W, Liu L, Yang J, et al., “MicroRNA-146b correlates with decreased acute respiratory distress syndrome risk, reduced disease severity, and lower 28-day mortality in sepsis patients[J],” J Clin Lab Anal, vol. 34, no. 12, pp. 1–9, 2020.